HOW WOULD YOU COMBINE RISK AND MEDICAL DEVICE PROJECTS?
PRESENTED BY FRANCESCO CARNABUCIENGINEERING MANAGER – R&D DISPOSABLE
12 June 2019
2
SPEAKER SPOTLIGHT: FRANCESCO CARNABUCIENGINEERING MANAGER R&D DISPOSABLE, BELLCO – MEDTRONIC Aeronautical EngineerSix sigma green beltTechnical consultant at Modena CourtProfessional Project Manager
PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
MEDICAL TECHNOLOGY IS WHAT WE DO. IT’S WHAT WE’VE ALWAYS DONE. You may know us as the pacemaker company, the diabetes pump maker, or deep-brain stimulation experts and we do so much more.
3 PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
Since the late 1940s, we have been working with others to alleviate pain, restore health, and extend life.
FOUNDED ON INNOVATION AND COLLABORATION Surgeon
C. Walton Lilleheiin 1961, with a young patient wearing a Medtronic battery-operated pacemaker.
Our founder, Earl Bakken, who —together with his brother-in-law, Palmer Hermundslie —started Medtronic out of a small Midwestern garage in 1949.
PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only4
OUR RICH HISTORY OF INNOVATIONHOW WE’VE GROWN OVER THE YEARS
ACQUIRED COVIDIEN
19601949 1977 1983 1999 2001 2002 2015 2016
WROTE OUR MISSION
INTRODUCED PROSTHETIC HEART VALVE
EXPANDED INTO SPINAL CARE
MEDTRONICIS FOUNDED
EXPANDED INTO NEURO-STIMULATION
EXPANDEDINTO DIABETES CARE
INTRODUCEDFIRST REMOTE MONITORING SYSTEM
ACQUIRED BELLCO
INTRODUCED THE WORLD’S SMALLEST PACEMAKERAND THEFIRST HYBRIDCLOSED LOOP INSULIN DELIVERY SYSTEM
CREATED FIRST BATTERY-OPERATED, EXTERNAL PACEMAKER
1957
ESTABLISHED THE MEDTRONIC FOUNDATION
1979
Developed the first implantable pacemaker
2018
ACQUIRED CLEARUM
INTRODUCED THE WORLD'S SMALLEST IMPLANTABLE SPINAL CORD STIMULATOR
5 PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
6
OVERVIEW OF BELLCO COMPANYMEDTRONIC BUSINESS UNIT
PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
7
INTEGRATION STATUS POINT
Bellco – Medtronic integration period, previous status point according to the Risk Spectrum seems be defined:
from BAD to OKAY
Medtronic, current status point according to the Risk Spectrum seems be defined:
from GOOD to BEST
PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
TODAY
8
WE BELIEVE IN IMPROVING LIVES WITH THE POWER OF INTEGRATED APPROACHAll MEDTRONIC/BELLCO functions execute and participate in risk management activities from voice of customer to last product use.
Research and Development
Quality Assurance / Quality Control
Operations / Supply Chain
Medical and Safety Office
Sales / Servicing / Marketing
PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
9
HOW WOULD YOU COMBINE RISK AND MEDICAL DEVICE PROJECTS?LEVELS OF INTERVENTION
1. On top at Company level: Enterprise Risk Management
Enterprise risk management at Medtronic follows a collaborative and deeply integratedmethodology that provides a sustainable framework to proactively identify, assess,mitigate and report global strategy, financial and legal & compliance risks, bothexisting and emerging, in support to our core growth strategies and the MedtronicMission.
2. In the middle at Project level: Project Risk Management
Project risk management is part of an integrated development process workflow named Ideation to Market Release (ID2MR)
3. From down at Product level: Product Risk Management
Product risk management is part of Design Control process. Design Control is the formal methodology for conducting product development activities ensuring products meets established requirements. The purpose of Design Control is to, ensuring aneffective, repeatable, and compliant development process support the development of safe and effective medical devices
PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
10
PROJECT RISK MANAGEMENT PROCESSIDEATION TO MARKET RELEASE (ID2MR)
PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
11
PROJECT RISK MANAGEMENT PROCESSIDEATION TO MARKET RELEASE (ID2MR)
Why is ID2MR?
To address historic project outcomes• Lack of Predictability
• Time: Schedule error = 38%• Budget: Forecasting error = 69%
• Lengthy Development Cycles• Platform Projects = 23 months (goal ≤ 18)• Derivative Projects = 14 months (goal ≤ 9)
• Poor Launch Outcomes• Field Corrective Actions = 12 in FY16-17
• Employee Engagement Score• "Getting work done around here is easy"• "Employees are encouraged to try new ways of working"
PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
12
PROJECT RISK MANAGEMENT PROCESSIDEATION TO MARKET RELEASE (ID2MR)
Project Risk AssessmentThe objective is to identify the project risks that prevent theteam from committing to a ±10% launch window and±10% budget at the end of Phase 4. Those risks areidentified in Phase 2, and mitigation activities for Phase 3are planned and approved. These "project" risks includetechnology, manufacturing process, supplier selection andcapability, inspection, clinical, service and repair,component end of life, product risks (identified in a riskassessment), etc.
PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
13
PROJECT RISK MANAGEMENT PROCESSIDEATION TO MARKET RELEASE (ID2MR)
Product Risk Burn-downThe intent is NOT to burn down all project risk; just thehigh-risk items that could result in major project delaysin Phases 5-6 if not resolved earlier
PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
14 PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
PRODUCT RISK MANAGEMENT PROCESSAN INTEGRATED APPROACHProduct Risk Management Process in compliance to the Essential Requirements of the European Directive 93/42/EEC on Medical Devices and to ISO 14971 consists of the following basic elements:
Risk Analysis
Identifying the hazardous situations and severity of the harms associated with the hazardous situations, taking into account the intended use and reasonably foreseeable misuse of the product,
Estimating the individual risks taking into account the severity and the probability of occurrence of the harms,
Risk Evaluation
Evaluating the individual risks against established acceptability criteria.
Risk Control
Controlling the risks to ensure that they do not exceed acceptable limits,
Implementing risk control measures and evaluating risks arising from these additional measures,
Evaluating the residual risks to assess whether additional risk control measures are needed,
Production and Post-production information
Monitoring the internal and field commercial performance of the product to assess the effectiveness of the original risk management activities and the need for additional risk controls.
15
PRODUCT RISK MANAGEMENT PROCESSAN INTEGRATED APPROACH
How the risk management process steps are applied throughout the product lifecycle?
Risk Management Plan (RMP)
Preliminary Hazard Analysis (PHA)
Failure Mode Effect and Analysis (FMEA)
Risk Analysis Chart (RAC)
Combined PHA and RAC
Risk Management Report (RMR)
Post-Market Surveillance Report
Project Tasks / Deliverables
Project Phases
Risk Management Plan Concept / Feasibility
Preliminary Hazard Analysis
Design Development
Applicable FMEA(s) Design Development
Process FMEA Design Evaluation
Risk Analysis Chart or combined PHA & RAC
Design Development
Risk Management Report
Design Evaluation
Post-Market Surveillance Report
Post Market
PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
16
PRODUCT RISK MANAGEMENT PROCESSAN INTEGRATED APPROACH
There are multiple factors in the determination of the Probability ofOccurrence of Harm. The first factor is the probability of the hazardoussituation occurring (P1), the second factor is the probability of thehazardous Situation leading to harm (P2), and the final is the probabilityof occurrence of harm (P1 cross P2):
ScoreSeverity of Harm
Definition
5 Catastrophic Results in patients death, or catastrophic property or environmental damage
4 Critical Results in permanent impairment or life threatening injury, or critical property or environmental damage
3 MajorResults in injury or impairment requiring major professional medical intervention, or serious property or environmental damage
2 MinorTemporary injury or impairment that requires minor professional medical intervention, or minor property or environmental damage
1 NegligibleResults in temporary injury or impairment that does not require professional medical intervention; inconvenience
Severity (SEV) table ranking
Severity of HarmCatastrophic
(5) Critical(4)
Major(3)
Minor(2)
Negligible(1)
Prob
ability of H
arm
(P1 x P2
)
Frequent(5) 3 3 3 2 2
Probable(4) 3 3 2 2 1
Occasional(3) 3 3 2 1 1
Remote(2) 3 2 2 1 1
Improbable(1) 2 2 1 1 1
Risk Zone Structure
PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
FURTHER, TOGETHERCASE STUDYNEW HIGH FLUX DIALYZER PROJECT
PROJECT RISK MANAGEMENT: NEW HIGH FLUX DIALYZER PROJECTNEW HIGH FLUX DIALYZER PROJECT
18 PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
Project Scope: release of a new MDD - CE marked high-flux dialyzersfamily based on a new membrane manufactured.
RISK MANAGEMENT STRATEGY:Perform regular project risk assessments on project levelOnce a month bring 5 top risks to the Project Risk Assessmentmeeting (separate meeting). Present the risks, their ranks, ownersand the proposed mitigations.
19 PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
PROJECT RISK MANAGEMENT: NEW HIGH FLUX DIALYZER PROJECTNEW HIGH FLUX DIALYZER PROJECT
N. Risk description Action Grade Trend Owner
1 Product Clinical-related Safety may stop the projectMitigate: clinical safety related test early started and done: no concern
Low stable SA
2
Manufacturing Line Improvement delay impacts heavily on project due date. Potential causes:•External supplier delay - SINTECO•Process Validation delay
Mitigate: •set recurrent meeting with SINTECO•early start PV activities to anticipate potential issues
Medium stable MFE
3Steam Sterilization with observed performance data variability may lead to high lot-lot variability during DVT
Mitigate: lot-lot performance variability evaluation in DVT with testing methods fine tuned to lower test method variability
Low stable R&D
4
Clearum HF11: mold D32PP has to be adjusted, impact and timings are still under evaluation; in the best case PQ samples will be available in mid July (2 months beyond other models availability) with the current MFE activity pipeline high impacts may lead to further delay HF11 samples availability and release
Avoided: keep-on with models starting from filtering surfaces 1.3 to 2.2. Introduction of 1.1 to be planned in other stream upon dedicated MKT business case release.
High N/A
MFE / external supplier
CGM / MKT
5 Shelf life of the supplier is 2 yy, while shelf life of dialyzers are 3yy additional: this might lead to potential specs deviation
Avoid: plan for product verification at the specs limits
High decrease R&D
CURRENT TOP FIVE HIGH-LEVEL PROJECT RISKS
PROJECT RISK MANAGEMENT: TOOLS TO USE
20
Do not re-invent the weel!
Project Risk Ranking is the same for the product and project.
PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
NEW HIGH FLUX DIALYZER PROJECT
PROJECT RISK MANAGEMENT: TOOLS TO USE
21
Project Risk Model
PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
Negligible Minor Serious Critical Catastrophic
Improb
able
Remote
Occasiona
lProb
able
Freq
uent
Consequence Impact
Occ
urre
nce
prob
abili
ty
4
8
12
8 12
16
24
24
32
32
36
16
16
20
20
40
40
48
48
60
60
80
8064
100
2
2
Project Risk ID.2:Manufacturing Line Improvement delay impacts heavily on project due date. Potential causes:•External supplier delay - SINTECO•Process Validation delay
PROJECT RISK CATEGORIES: 1. RESOURCE RISKS1. Organization COMMITMENT
Are project resources sufficient? (Management, testers, QA, etc.)
Are there well-determined processes for R&D and Manufacturing engineering and project management?
Does the project team have authority to complete project work? Does it have influence to secure all inputs?
2. Financing BUDGET
Are the fundings adequate and sufficient to complete project?
Are the fundings secured?
Are there fundings allocated for training?
Are project costs assessed accurately?
3. People ENGAGEMENT
Are there enough employees available in the project?
Do these employees have appropriate skills and experience?
Have the employees worked together before?
Do the employees believe in project succeeding and take measures to strengthen it?
Have customers and user representatives participated in product reviews?
Do crucial experts participate in the project?
Is project schedule realistic?
Is the delivery date critical?
22 PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
PROJECT RISK CATEGORIES: 2. BUSINESS RISKS
Business FORECASTING
Are there potential consequences on the project (scope, funding, existence) if a competitor reaches the market first?
Is projected cost worth projected product value?
Are key suppliers secured?
Are stakeholders expectations still valid?
Are there any legal risks (contracts, regulatory obligations, etc.)?
23 PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
PROJECT RISK CATEGORIES: 3. TECHNICAL RISKS1. Scope Risks PROJECT SCOPE
Are requirements properly designed and well understood by staff?
Is project scope stable or does it keep expanding?
Are there tools/processes to measure project progress and success?
2. Technological Risks KNOW HOW
Have technology been proven?
Are there challenging technical requirements with which the project team is unfamiliar?
Does the project success depend on new, untried, or unproven technologies, HW, SW, or techniques?
Are there external dependencies to other systems including those outside the organization?
Are product users experienced and skilled?
Is product system complexity manageable?
3. External Dependency Risks CROSS-FUNCTIONAL
Does the project depend on parallel project development?
Does the project success depends on externally-developed components?
Do integration of development tools (design tools, compilers, etc.) and implementation technologies (OS, databases, communication mechanisms, etc.) have an impact to the project success?
Does the project have a back-up plan for completing without mentioned technologies?
24 PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
CONCLUSIONS
Risk management is not only a process but also a mindset.
Risk is a potential probability to suffer loss, We want to minimize the probability to suffer loss !
Enterprise, project and product risk management is expression of organization maturity level.
Address risks early in a project is the winner strategy to reduce costs and development time
The integrated approach, especially in the medical device field, is the alone way to conduct well a project.
A complete integration of a small/medium company in a worldwide company needs a passage across a structured process to conduct project and address risks.
25 PMI Risk Management | 12 June 2019 | Confidential, for Internal Use Only
Q&A
THANKS FOR YOUR ATTENTION AND FOR THIS GREAT OPPORTUNITY
Francesco CarnabucI
3484412524